Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion

Details

Serval ID
serval:BIB_FD8BC356C850
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion
Journal
Cytokine
Author(s)
Gerain  J., Lienard  D., Pampallona  S., Baumgartner  M., Ruegg  C., Buurman  W. A., Eggermont  A., Lejeune  F.
ISSN
1043-4666 (Print)
Publication state
Published
Issued date
12/1997
Volume
9
Number
12
Pages
1034-42
Notes
Clinical Trial
Clinical Trial, Phase II
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Dec
Abstract
Isolated limb perfusion (ILP) with high dose tumour necrosis factor (TNF), interferon gamma and melphalan (TIM) is an efficient treatment for patients with regionally advanced melanoma and sarcoma. In 44 patients, we determined the kinetics of soluble TNF receptors (sTNF-RI and RII) plasma concentrations, and correlated them with systemic TNF and interleukin 6 (IL-6) levels and shock. Seven patients treated conventionally by ILP without cytokine served as controls. Elevated levels of both sTNF-Rs were observed within 30 min after beginning of the TIM-ILP. A first peak of sTNF-Rs levels was observed 3 h after ILP and was followed by a rapid decrease reaching a nadir at 12-14 h post ILP. This first peak was followed by a second, long-lasting elevation of both sTNF-Rs levels persisting for 4 to 5 days after TIM-ILP. Patients treated by ILP without TNF/interferon gamma (IFN-gamma) had no detectable increase in either sTNF-Rs or in circulating TNF, demonstrating that the release of TNF-Rs was dependent upon the administration of TNF/IFN-gamma. High plasma levels of TNF and IL-6 were observed in patients that had more than 5% leakage during the TIM-ILP, but no significant correlation between TNF levels and the peak values of both sTNF-Rs was observed. The levels of TNF and IL-6 were, however, significantly related to each other. TNF systemic levels, but not sTNF-Rs concentrations, correlated significantly with the severity of the shock observed after TIM-ILP. Patients in which sTNF-RII concentration was in excess over circulating TNF, had no shock or grade I shock only, suggesting that sTNF-RII may play a protective, although limited, role in inhibiting activity of circulating TNF.
Keywords
Chemotherapy, Cancer, Regional Perfusion Humans Interferon-gamma, Recombinant/administration & dosage/adverse effects/*therapeutic use Interleukin-6/analysis/biosynthesis Melanoma/pathology/therapy Neoplasm Staging Receptors, Tumor Necrosis Factor/*biosynthesis/blood Recombinant Proteins/administration & dosage/adverse effects/therapeutic use Sarcoma/therapy Shock, Septic/blood Soft Tissue Neoplasms/therapy Tumor Necrosis Factor-alpha/administration & dosage/adverse effects/*therapeutic use
Pubmed
Web of science
Create date
28/01/2008 8:36
Last modification date
20/08/2019 16:28
Usage data